Prophylaxis, preemption and drug resistance in CMV infection: Too little, too much or just right?

American Journal of Transplantation

Volumn 12, Issue 1, 2012, Pages 13-14

  Fishman, J A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; TACROLIMUS; VALGANCICLOVIR;

ANTIBIOTIC THERAPY; ANTIVIRAL RESISTANCE; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG TREATMENT FAILURE; EDITORIAL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; VIREMIA;

CYTOMEGALOVIRUS; DRUG RESISTANCE, VIRAL; HUMANS; KIDNEY TRANSPLANTATION;

EID: 84855926060     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03764.x     Document Type: Editorial

References (5)

1. Lurain NS, Chou S,. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689-712.
2. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
3. Myhre HA, Haug Dorenberg D, Kristiansen KI, et al,. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011; 92: 217-223.
4. Couzi L, Helou S, Bachelet T, et al,. High incidence of anti-cytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2011.
5. van der Beek MT, Berger SP, Vossen AC, et al,. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: Comparison of treatment failure and antiviral resistance. Transplantation 2010; 89: 320-326.